168 related articles for article (PubMed ID: 22907167)
1. Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy.
Seko Y; Akuta N; Suzuki F; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
Intervirology; 2013; 56(1):13-21. PubMed ID: 22907167
[TBL] [Abstract][Full Text] [Related]
2. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2011 Jun; 83(6):1016-22. PubMed ID: 21503914
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
4. Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma.
Takeyasu M; Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2012 Aug; 84(8):1199-207. PubMed ID: 22711347
[TBL] [Abstract][Full Text] [Related]
5. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
Hepatology; 2007 Nov; 46(5):1357-64. PubMed ID: 17657816
[TBL] [Abstract][Full Text] [Related]
6. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2009 Jun; 81(6):1032-9. PubMed ID: 19382270
[TBL] [Abstract][Full Text] [Related]
7. Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment.
Ogura S; Akuta N; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Kobayashi M; Suzuki F; Suzuki Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
Intervirology; 2009; 52(4):179-88. PubMed ID: 19546575
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis.
Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
Intervirology; 2013; 56(1):37-45. PubMed ID: 23037768
[TBL] [Abstract][Full Text] [Related]
9. Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2008 Aug; 80(8):1354-62. PubMed ID: 18551609
[TBL] [Abstract][Full Text] [Related]
10. Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development.
Nakamoto S; Imazeki F; Fukai K; Fujiwara K; Arai M; Kanda T; Yonemitsu Y; Yokosuka O
J Hepatol; 2010 Jan; 52(1):72-8. PubMed ID: 19910070
[TBL] [Abstract][Full Text] [Related]
11. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
Miyasaka A; Kumagai I; Abe K; Suzuki K
Hepatogastroenterology; 2012 May; 59(115):794-9. PubMed ID: 22020909
[TBL] [Abstract][Full Text] [Related]
12. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
13. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Matsuda M; Kobayashi M; Arase Y; Ikeda K; Kumada H
Intervirology; 2005; 48(6):372-80. PubMed ID: 16024941
[TBL] [Abstract][Full Text] [Related]
14. Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b.
Kobayashi M; Akuta N; Suzuki F; Hosaka T; Sezaki H; Kobayashi M; Suzuki Y; Arase Y; Ikeda K; Watahiki S; Mineta R; Iwasaki S; Miyakawa Y; Kumada H
J Med Virol; 2010 Jan; 82(1):41-8. PubMed ID: 19950230
[TBL] [Abstract][Full Text] [Related]
15. Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis.
Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Hara T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
Hepatology; 2012 Dec; 56(6):2134-41. PubMed ID: 22806754
[TBL] [Abstract][Full Text] [Related]
16. Sequence variability of HCV Core region: important predictors of HCV induced pathogenesis and viral production.
Khaliq S; Jahan S; Pervaiz A
Infect Genet Evol; 2011 Apr; 11(3):543-56. PubMed ID: 21292033
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
[TBL] [Abstract][Full Text] [Related]
19. Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens.
Ogata F; Akuta N; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Suzuki F; Arase Y; Ikeda K; Kumada H
J Med Virol; 2018 Jun; 90(6):1087-1093. PubMed ID: 29427443
[TBL] [Abstract][Full Text] [Related]
20. A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B.
Murayama M; Katano Y; Nakano I; Ishigami M; Hayashi K; Honda T; Hirooka Y; Itoh A; Goto H
J Med Virol; 2007 Jan; 79(1):35-40. PubMed ID: 17133546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]